Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Growth 2025-2031

The global 23-Valent Pneumococcal Polysaccharide Vaccine market size is predicted to grow from US$ 1185 million in 2025 to US$ 2176 million in 2031; it is expected to grow at a CAGR of 10.7% from 2025 to 2031.

23-Valent Pneumococcal Polysaccharide Vaccine is a kind of vaccine used to prevent infection caused by pneumococcal bacteria. 23-Valent Pneumococcal Polysaccharide Vaccine contains 23 of the most common types of pneumococcal bacteria. 23-Valent Pneumococcal Polysaccharide Vaccine is for use only in adults and children who are at least 2 years old. For children younger than 2 years old, another vaccine called Prevnar (pneumococcal conjugate vaccine [PCV] 7-valent) is used, usually given between the ages of 2 months and 15 months.

Market Drivers:

The 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23) market is driven by the increasing prevalence of pneumococcal infections, particularly among high-risk populations such as the elderly, children, and immunocompromised individuals. Governments and health organizations worldwide are promoting vaccination programs to reduce the burden of pneumococcal diseases, which has significantly boosted market growth. Additionally, rising awareness about the importance of preventive healthcare and advancements in vaccine manufacturing technologies contribute to the increased adoption of PPSV23 vaccines.

Market Challenges:

However, the market faces challenges such as the high cost of vaccination, which limits accessibility in low- and middle-income countries. Moreover, the competition from newer pneumococcal conjugate vaccines (PCVs), which offer broader coverage and are preferred for pediatric use, poses a threat to PPSV23's market share. Another concern is vaccine hesitancy and misinformation, which can hinder immunization efforts and impact the overall market growth.

Merck is the largest manufacturers of 23-Valent pneumococcal polysaccharide vaccine in the world, has a share about 78%. Other players include Sinovac, Kangtai Bio, CDIBP, Walvax, etc. United States is dominating the global 23-Valent pneumococcal polysaccharide vaccine market, has a share nearly 78% in terms of production. The largest market is United States, holds a share about 48%, followed by China and Europe, with around 25% and 22% market share respectively.

LP Information, Inc. (LPI) ' newest research report, the “23-Valent Pneumococcal Polysaccharide Vaccine Industry Forecast” looks at past sales and reviews total world 23-Valent Pneumococcal Polysaccharide Vaccine sales in 2024, providing a comprehensive analysis by region and market sector of projected 23-Valent Pneumococcal Polysaccharide Vaccine sales for 2025 through 2031. With 23-Valent Pneumococcal Polysaccharide Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world 23-Valent Pneumococcal Polysaccharide Vaccine industry.

This Insight Report provides a comprehensive analysis of the global 23-Valent Pneumococcal Polysaccharide Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on 23-Valent Pneumococcal Polysaccharide Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global 23-Valent Pneumococcal Polysaccharide Vaccine market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for 23-Valent Pneumococcal Polysaccharide Vaccine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global 23-Valent Pneumococcal Polysaccharide Vaccine.

This report presents a comprehensive overview, market shares, and growth opportunities of 23-Valent Pneumococcal Polysaccharide Vaccine market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:
Single Dose Vial
Pre-filled Syringe

Segmentation by Application:
For Children (Over 2 Years Old)
For Adult

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Merck
Sinovac
Kangtai Bio
CDIBP
Walvax

Key Questions Addressed in this Report

What is the 10-year outlook for the global 23-Valent Pneumococcal Polysaccharide Vaccine market?

What factors are driving 23-Valent Pneumococcal Polysaccharide Vaccine market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do 23-Valent Pneumococcal Polysaccharide Vaccine market opportunities vary by end market size?

How does 23-Valent Pneumococcal Polysaccharide Vaccine break out by Type, by Application?

Please note: The report will take approximately 2 business days to prepare and deliver.